CH618345A5 - - Google Patents
Download PDFInfo
- Publication number
- CH618345A5 CH618345A5 CH1032174A CH1032174A CH618345A5 CH 618345 A5 CH618345 A5 CH 618345A5 CH 1032174 A CH1032174 A CH 1032174A CH 1032174 A CH1032174 A CH 1032174A CH 618345 A5 CH618345 A5 CH 618345A5
- Authority
- CH
- Switzerland
- Prior art keywords
- interferon
- support
- virus
- pharmaceutical form
- fixed
- Prior art date
Links
- 102000014150 Interferons Human genes 0.000 claims description 86
- 108010050904 Interferons Proteins 0.000 claims description 86
- 229940079322 interferon Drugs 0.000 claims description 86
- 239000011324 bead Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- 229920002307 Dextran Polymers 0.000 claims description 7
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- -1 Tin Polysaccharide Chemical class 0.000 claims description 4
- 239000011543 agarose gel Substances 0.000 claims description 4
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 150000004804 polysaccharides Polymers 0.000 claims description 3
- 229920000936 Agarose Polymers 0.000 claims description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
- 229920000057 Mannan Polymers 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- 229960002897 heparin Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229920001221 xylan Polymers 0.000 claims description 2
- 150000004823 xylans Chemical class 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 150000004676 glycans Polymers 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 24
- 229920002684 Sepharose Polymers 0.000 description 20
- 241000710188 Encephalomyocarditis virus Species 0.000 description 17
- 241000700605 Viruses Species 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 12
- 239000000872 buffer Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 10
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 241000711975 Vesicular stomatitis virus Species 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 241000307523 Xenostegia media Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001064 anti-interferon Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- ZAQGNUYHFOEELE-FTQKVMGASA-N (2r,3s,4r,5s)-2,3,4,5,6-pentahydroxy-6-[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]hexanal Chemical compound OC[C@H]1OC(C(O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@@H](O)[C@@H]1O ZAQGNUYHFOEELE-FTQKVMGASA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- WQZGKKKJIJFFOK-SVZMEOIVSA-N D-(+)-Galactose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920000869 Homopolysaccharide Polymers 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-M alpha-D-galacturonate Chemical compound O[C@H]1O[C@H](C([O-])=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-M 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003067 hemagglutinative effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7327538A FR2244543B1 (enExample) | 1973-07-27 | 1973-07-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH618345A5 true CH618345A5 (enExample) | 1980-07-31 |
Family
ID=9123222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1032174A CH618345A5 (enExample) | 1973-07-27 | 1974-07-26 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4041152A (enExample) |
| JP (1) | JPS50116618A (enExample) |
| CH (1) | CH618345A5 (enExample) |
| DE (1) | DE2436172A1 (enExample) |
| FR (1) | FR2244543B1 (enExample) |
| GB (1) | GB1482132A (enExample) |
| SE (1) | SE7409732L (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1983001899A1 (en) * | 1981-12-01 | 1983-06-09 | BÉLADI, Ilona | Process for the production of human gamma-interferon |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2351665A1 (fr) * | 1976-05-21 | 1977-12-16 | Elf Aquitaine | Procede de purification de preparations possedant notamment une activite interferon, preparations purifiees ainsi obtenues et leur application en tant que medicament |
| US4503035B1 (en) * | 1978-11-24 | 1996-03-19 | Hoffmann La Roche | Protein purification process and product |
| IN150740B (enExample) * | 1978-11-24 | 1982-12-04 | Hoffmann La Roche | |
| SE445013B (sv) * | 1979-06-21 | 1986-05-26 | Landstingens Inkopscentral | Medel for att forebygga eller behandla infektioner hos menniskor och djur |
| US4289689A (en) * | 1980-03-14 | 1981-09-15 | Hoffmann-La Roche Inc. | Preparation of homogeneous human fibroblast interferon |
| JPS5651995A (en) * | 1979-10-05 | 1981-05-09 | Green Cross Corp:The | Preparation of interferon |
| JPS5823847B2 (ja) * | 1981-02-06 | 1983-05-18 | 株式会社 林原生物化学研究所 | 抗ヒト蛋白質抗体の製造方法 |
| EP0090837A1 (en) * | 1981-10-08 | 1983-10-12 | BERG, Kurt Frimann | Method and composition for treating a patient suffering from interferonsusceptible disorder |
| EP0150067A3 (en) * | 1984-01-23 | 1986-12-30 | Takeda Chemical Industries, Ltd. | Stable composition of gamma-interferon |
| US4745180A (en) * | 1986-06-27 | 1988-05-17 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using heparin fragments |
| JPH04503607A (ja) * | 1989-02-24 | 1992-07-02 | イムノセラピューティックス・インコーポレイテッド | 固定化サイトカイン類 |
| EP0790062B1 (en) * | 1995-08-30 | 2006-05-10 | Toray Industries, Inc. | Method of testing for myocarditis and cariomyopathy |
| WO2001026677A1 (fr) * | 1999-10-12 | 2001-04-19 | Santen Pharmaceutical Co., Ltd. | Complexe a base d'interferon et son utilisation en medecine |
| WO2006026678A2 (en) * | 2004-08-31 | 2006-03-09 | Le Centre National De La Recherche Scientifique | Method for downregulating an immune reaction |
| CN101184780B (zh) | 2005-05-05 | 2012-10-03 | 森馨香料公司 | β-葡聚糖和甘露聚糖的制备 |
-
1973
- 1973-07-27 FR FR7327538A patent/FR2244543B1/fr not_active Expired
-
1974
- 1974-07-22 US US05/490,658 patent/US4041152A/en not_active Expired - Lifetime
- 1974-07-26 CH CH1032174A patent/CH618345A5/fr not_active IP Right Cessation
- 1974-07-26 JP JP49085943A patent/JPS50116618A/ja active Pending
- 1974-07-26 SE SE7409732A patent/SE7409732L/xx unknown
- 1974-07-26 DE DE2436172A patent/DE2436172A1/de not_active Withdrawn
- 1974-07-26 GB GB33136/74A patent/GB1482132A/en not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1983001899A1 (en) * | 1981-12-01 | 1983-06-09 | BÉLADI, Ilona | Process for the production of human gamma-interferon |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2244543B1 (enExample) | 1977-07-01 |
| SE7409732L (enExample) | 1975-01-28 |
| DE2436172A1 (de) | 1975-02-13 |
| JPS50116618A (enExample) | 1975-09-12 |
| GB1482132A (en) | 1977-08-03 |
| US4041152A (en) | 1977-08-09 |
| FR2244543A1 (enExample) | 1975-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Taylor et al. | Protamine is an inhibitor of angiogenesis | |
| Nakashima et al. | Purification and characterization of an avian myeloblastosis and human immunodeficiency virus reverse transcriptase inhibitor, sulfated polysaccharides extracted from sea algae | |
| Vogt | Anaphylatoxins: possible roles in disease | |
| Zhang et al. | Synthesis, characterization and immunogenicity of silk fibroin-L-asparaginase bioconjugates | |
| JP5868356B2 (ja) | 血液からの病原性微生物、炎症性細胞または炎症性タンパク質の体外除去法 | |
| US4041152A (en) | Pharmaceutical formulation of interferon insolubilized by fixation on a support | |
| JPH09328431A (ja) | 抗炎症活性を有する硫酸化ポリサッカライド | |
| EP4362960A1 (fr) | Materiau biologique impregne d'une solution comprenant des exosomes | |
| CN114306581A (zh) | 一种融合细胞膜包裹尿酸酶/过氧化氢酶脂质纳米粒及其制备方法 | |
| JP2000508535A (ja) | 固定化アリイナーゼおよびアリシンの連続生産 | |
| JPH09511220A (ja) | バクテリアによって誘発される炎症性疾患の治療 | |
| BE1005641A3 (fr) | Composition vegetale de faible poids moleculaire et sa preparation. | |
| EP0088022B1 (fr) | Agents antitumoraux à efficacité améliorée, leur obtention et procédé pour augmenter l'efficacité des agents antitumoraux | |
| FR2504928A1 (fr) | Oligosaccharides a chaines courtes possedant des proprietes biologiques, leur preparation et leurs applications en tant que medicaments | |
| JP2010503665A (ja) | 経口剤の形状でインスリンを作製する方法 | |
| JPH03503640A (ja) | 血液処理の方法および手段 | |
| JPS62255430A (ja) | 哺乳動物の脈管病を治療する方法 | |
| WO2003089000A2 (fr) | Composition anti-vih, comprenant un polyanion et un agent agissant sur gp120 de acon equivalent au cd4 | |
| Saito et al. | Effect of human interferon on different functions of human neutrophils and eosinophils | |
| Born et al. | Biological activity of the vegetalizing factor: Decrease after coupling to polysaccharide matrix and enzymatic recovery of active factor | |
| FR2495634A1 (fr) | Enzyme nouvelle et utilisable en therapeutique | |
| CH633716A5 (en) | Method for separating and purifying products having interferon activity, purified preparations having interferon activity and use of the preparations | |
| JPH06279292A (ja) | 生理活性を有するグリコーゲンの製法及び生理活性 | |
| WO1983004260A1 (fr) | Enzyme analogue de la pepsine de leucocyte humain et agent therapeutique contenant cette enzyme en tant qu'ingredient effectif pour le traitement de troubles allergiques, de maladies auto-immunitaires et de tumeurs | |
| JPH04187640A (ja) | 経口・経皮免疫機能促進剤、動物用経口・経皮免疫機能促進剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |